Merck & Company Inc. (new) ($MRK) Stock Forecast: Down 5.1% Today

What is Merck & Company Inc. (new)?

Merck & Co., Inc. ($MRK) is a leading pharmaceutical company known for its innovative healthcare solutions. Today, the stock experienced a strong bearish movement in the market.

Why is Merck & Company Inc. (new) going down?

MRK stock is down 5.1% on Apr 21, 2026 14:46

• Positive updates on Moderna's investigational mRNA therapeutics, particularly in melanoma treatment, may have overshadowed Merck's position in the market, leading to a bearish sentiment.
• The 52-week low hit by Boston Scientific's stock could have raised concerns about the overall performance of healthcare-related companies, impacting Merck's stock negatively.
• Despite positive analyst sentiment and institutional investments in Merck, the setback in a Phase 3 cancer drug trial might have contributed to the bearish movement as investors reevaluated the company's future prospects.
• The increased stake by Novem Group and the acquisition by SageGuard Financial Group LLC could indicate confidence in Merck's long-term potential, but the market may have reacted more strongly to the recent trial setback, resulting in the bearish trend.

MRK Price Chart

MRK Technical Analysis

MRK News

Moderna lines up melanoma and myeloma data for ASCO in Chicago

Moderna announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 ASCO Annual Meeting. The presentations include a 5-year update on intismeran plus pembrolizumab in resected melanoma, and two poster presentations covering intismeran autogene as adjuvant therapy in melanoma and mRNA-2808 in multiple myeloma. Moderna will also host a live investor webcast on June 1 to discuss these presentations.

https://www.stocktitan.net/news/MRNA/moderna-announces-data-to-be-presented-at-2026-asco-annual-0fpp3w959zhz.html

Boston Scientific stock hits 52-week low at 60.54 USD

Boston Scientific's stock has hit a 52-week low, trading at $60.43, just below its official low of $60.59. Despite a challenging year with a nearly 35% decline, InvestingPro suggests the stock may be undervalued given its prominent position in the Healthcare Equipment & Supplies industry and strong 20% revenue growth. Analysts have issued mixed but generally optimistic updates, adjusting price targets while maintaining Buy or Outperform ratings.

https://www.investing.com/news/company-news/boston-scientific-stock-hits-52week-low-at-6054-usd-93CH-4626446

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

The AACR 2026 annual meeting saw new data presented from Moderna, Revolution Medicines, Zymeworks, and BeOne. Moderna's experimental antigen therapy mRNA-4359 showed an 83% overall response rate in melanoma patients when combined with Keytruda. Revolution Medicines updated its Phase 1 data for lung cancer drug zoldonrasib, demonstrating a 52% confirmed ORR and 11.1 months median progression-free survival. Zymeworks presented "encouraging but early" data for zanidatamab in early-stage HER2-positive breast cancer, suggesting it could reduce the need for chemotherapy, while BeOne's Tevimbra combinations in head and neck squamous cell carcinoma did not show added benefit over monotherapy.

https://www.biospace.com/drug-development/aacr-2026-moderna-revolution-zymeworks-and-beone-showcase-new-data

Novem Group Purchases 9,205 Shares of Merck & Co., Inc. $MRK

Novem Group increased its stake in Merck & Co., Inc. by 23.1% in the fourth quarter, now owning 48,989 shares valued at $5.16 million. Despite recent insider selling, institutional investors hold 76.07% of the stock. Merck faces mixed news with new FDA priority reviews and EU approvals, alongside a setback in a Phase 3 cancer drug trial.

https://www.marketbeat.com/instant-alerts/filing-novem-group-purchases-9205-shares-of-merck-co-inc-mrk-2026-04-21/

SageGuard Financial Group LLC Acquires Shares of 14,280 Merck & Co., Inc. $MRK

SageGuard Financial Group LLC has acquired a new stake of 14,280 shares in Merck & Co., Inc. (NYSE:MRK), valued at approximately $1.50 million. The acquisition contributes to institutional investors owning around 76.07% of the stock. Analyst sentiment remains broadly positive, with a "Moderate Buy" consensus and a price target of $128.47, despite a recent setback from a failed Phase 3 trial.

https://www.marketbeat.com/instant-alerts/filing-sageguard-financial-group-llc-acquires-shares-of-14280-merck-co-inc-mrk-2026-04-21/

Trending Today

Deere & Company ($DE) Stock Forecast: Down 6.5% Today

International Business Machines Corporation ($IBM) Stock Forecast: Up 12.1% Today

Blink Charging Co. ($BLNK) Stock Forecast: Up 5.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 30.3% Today

Under Armour Inc. Class A ($UAA) Stock Forecast: Up 5.2% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 5.3% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.2% Today

Williams-Sonoma Inc. (DE) ($WSM) Stock Forecast: Up 7.9% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Up 5.6% Today

BlackLine, Inc. ($BL) Stock Forecast: Down 5.7% Today

Merck & Company Inc. (new) Price History

03.01.2026 - MRK Stock was up 2.0%

• Merck & Co. (MRK) stock saw an uptick following the release of robust Q4 2025 financial results and positive FY 2026 earnings outlook.
• Optimism surrounds Merck's acquisitions and broad pipeline diversification, especially looking beyond the exclusivity of Keytruda, driving the positive market sentiment.
• An educational campaign by Bristol Myers Squibb and Johnson & Johnson about the factor XIa pathway may be influencing the upward movement, shining a light on the potential of novel anticoagulants for cardiovascular and thromboembolic conditions.
• Positive remarks by Jim Cramer regarding Merck's future prospects and its expansion beyond Keytruda are likely bolstering investor confidence in the company's growth trajectory.

03.01.2026 - MRK Stock was up 6.2%

• Reported impressive Q4 2025 sales and profit figures, beating analyst estimates, driven by strong demand for KEYTRUDA and benefits from recent acquisitions.
• Despite the positive earnings, the cautious 2026 outlook, lower-than-expected guidance, and concerns over the impact of the Cidara acquisition led to initial pre-market stock decline.
• Analysts and experts remain optimistic about Merck's strategic acquisitions, diversified pipeline, and upcoming catalysts, highlighting the company's long-term potential.
• The market seems to be balancing Merck's current financial performance with future growth prospects and potential challenges in specific product sales, such as GARDASIL in China.

21.03.2026 - MRK Stock was down 5.1%

• Positive updates on Moderna's investigational mRNA therapeutics, particularly in melanoma treatment, may have overshadowed Merck's position in the market, leading to a bearish sentiment.
• The 52-week low hit by Boston Scientific's stock could have raised concerns about the overall performance of healthcare-related companies, impacting Merck's stock negatively.
• Despite positive analyst sentiment and institutional investments in Merck, the setback in a Phase 3 cancer drug trial might have contributed to the bearish movement as investors reevaluated the company's future prospects.
• The increased stake by Novem Group and the acquisition by SageGuard Financial Group LLC could indicate confidence in Merck's long-term potential, but the market may have reacted more strongly to the recent trial setback, resulting in the bearish trend.

30.02.2026 - MRK Stock was down 1.4%

• Merck (MRK) experienced a bearish movement despite positive news surrounding its recent acquisition of Terns Pharmaceuticals and strong Q4 earnings.
• The increased investment by WESPAC Advisors LLC did not seem to positively impact MRK's stock performance today.
• The growth in the Non-Muscle Invasive Bladder Cancer (NMIBC) market, where Merck is a key player, did not translate into a positive market movement for the company.
• Jim Cramer's advice to "stay the course" with MRK stock did not prevent the bearish trend today, indicating other market factors at play.

08.00.2026 - MRK Stock was up 3.3%

• Merck's stock price surged following an upgrade from Wolfe Research to Outperform from Peer Perform, showcasing optimism and confidence in the company's growth outlook.
• Identification as a top long-term growth stock by Zacks Investment Research heightened investor interest in Merck, propelling the stock upwards.
• A strategic partnership between Veeva Systems and BioMarin Pharmaceutical, though unrelated to Merck, underlines industry collaborations that could have a positive impact on market sentiment.
• United Asset Strategies Inc. raised its stake in Merck, indicating institutional confidence in the company's future performance and strategic endeavors.